1-Jahres-Chart
5-Tage-Chart
| Realtime | Geld | Brief | Zeit |
|---|---|---|---|
| 2,360 | 2,580 | 02.03. |
- Alle
- Pressemitteilungen
- Empfehlungen
- Chartanalysen
- Berichte
| Zeit | Aktuelle Nachrichten Sprache:
Alle DE EN | Leser | Medien | ||
|---|---|---|---|---|---|
| 05.02. | Aclarion, Inc.: Aclarion Publishes 2026 Shareholder Letter from the Chairman | 162 | GlobeNewswire (Europe) | Company anticipates no capital raises prior to expected value enhancing catalysts Cash runway into 2028ATM terminated in early 2025 and ELOC expired December 31, 2025 BROOMFIELD, Colo., Feb. 05, 2026... ► Artikel lesen | |
| ACLARION Aktie jetzt für 0€ handeln | |||||
| 03.02. | Aclarion partners with Source Healthcare to expand Nociscan availability | 1 | Investing.com | ||
| 03.02. | Aclarion erweitert Verfügbarkeit von Nociscan durch Partnerschaft mit Source Healthcare | 2 | Investing.com Deutsch | ||
| 03.02. | Aclarion, Inc.: Aclarion Adds High-Volume Practice, Source Healthcare, to Support Nociscan Growth and Real-World Evidence Generation | 1 | GlobeNewswire (USA) | ||
| 13.01. | Aclarion raises $10.4 million to fund chronic back pain technology | 3 | Investing.com | ||
| 13.01. | Aclarion schließt Finanzierung über 10,4 Millionen US-Dollar für Technologie gegen Rückenschmerzen ab | 8 | Investing.com Deutsch | ||
| 13.01. | Aclarion, Inc.: Aclarion Strengthens Balance Sheet and Extends Cash Runway Into 2028 | 415 | GlobeNewswire (Europe) | BROOMFIELD, Colo., Jan. 13, 2026 (GLOBE NEWSWIRE) -- Aclarion, Inc., ("Aclarion" or the "Company") (Nasdaq: ACON, ACONW), a commercial-stage healthcare technology company that is leveraging biomarkers... ► Artikel lesen | |
| 09.01. | Aclarion, Inc. - 8-K, Current Report | 2 | SEC Filings | ||
| 08.01. | Aclarion Stock Climbs 50% After Strong 2025 Results And 2026 Outlook | 9 | RTTNews | ||
| 08.01. | Aclarion-Aktie steigt sprunghaft an: Scan-Volumen von Nociscan im 4. Quartal um 114 % gewachsen | 11 | Investing.com Deutsch | ||
| 08.01. | Aclarion's AI Back Pain Tech Sees 114% Surge In Demand, Stock Soars | 9 | Benzinga.com | ||
| 08.01. | Aclarion to enroll around 25% of patients in CLARITY trial by Q2 | 3 | Seeking Alpha | ||
| 08.01. | Aclarion, Inc.: Aclarion Provides 2025 Update and 2026 Corporate Outlook | 194 | GlobeNewswire (Europe) | Quarterly Nociscan scan volumes increased 114% year-over-year in Q4 2025Annual Nociscan scan volumes increased 69% year-over-year in 2025Debt-free balance sheet with $12.0 million in cash as of December... ► Artikel lesen | |
| 06.01. | Aclarion, Inc.: Aclarion Announces First Patient Enrollments at Two Additional CLARITY Trial Sites and Provides Guidance on Expected Availability of Initial Data | 99 | GlobeNewswire (Europe) | Northwestern and Scripps Health join two previously announced sites in achieving this critical patient enrollment milestone Seven leading U.S. spine centers have now completed the regulatory and operational... ► Artikel lesen | |
| 04.12.25 | Aclarion-Aktie steigt nach Vorstellung von Wirbelsäulen-Technologie in Fachjournal | 4 | Investing.com Deutsch | ||
| 04.12.25 | Aclarion's Nociscan featured in special pain issue of spine journal | 1 | Investing.com | ||
| 04.12.25 | Aclarion, Inc.: Aclarion Announces Publication of Nociscan Article in Special Pain Issue of the International Journal of Spine Surgery (IJSS) | 1 | GlobeNewswire (USA) | ||
| 12.11.25 | Aclarion: Interview With CEO Brent Ness About The Digital Health Company Addressing A Worldwide Epidemic | 4 | pulse2.com | ||
| 12.11.25 | Aclarion, Inc. - 10-Q, Quarterly Report | - | SEC Filings | ||
| 05.11.25 | Aclarion appoints first UK commercial director as insurance coverage expands | 1 | Investing.com |
1 2 3 Weiter >>
41 Nachrichten in den letzten 12 Monaten
| Unternehmen / Aktien | Aktienkurs | % | Top-Nachrichten | ||
|---|---|---|---|---|---|
| UNITEDHEALTH | 252,50 | -0,04 % | Former Optum CEO Heather Cianfrocco to depart UnitedHealth Group | ||
| INTUITIVE SURGICAL | 426,60 | +0,49 % | Im Krankenhaus auf Aktiensuche: Paul Hartmann, Technogym und Intuitive Surgical | Ein paar Dinge habe ich nach meinen Krankenhaus-Aufenthalten im November, Dezember und Januar gelernt...
...zum Beispiel: Es ist egal, wie schlecht es dir geht, es geht immer noch jemandem schlechter... ► Artikel lesen | |
| THERMO FISHER | 434,95 | +0,01 % | THERMO FISHER SCIENTIFIC INC. - 10-K, Annual Report | ||
| ROKU | 84,00 | +0,11 % | Citizens reiterates Roku stock rating on OEM partnerships, TV strategy | ||
| ATOSSA THERAPEUTICS | 0,001 | -100,00 % | XFRA 7300,B0Y,YAG: AUSSETZUNG/SUSPENSION | DAS/ DIE FOLGENDE(N) INSTRUMENT(E) IST/ SIND AB SOFORT AUSGESETZT:THE FOLLOWING INSTRUMENT(S) IS/ ARE SUSPENDED WITH IMMEDIATE EFFECT:INSTRUMENT NAME KUERZEL/SHORTCODE ISIN BIS/UNTILZEROSTACK CORP.... ► Artikel lesen | |
| EVOFEM BIOSCIENCES | - | - | Evofem Biosciences, Inc.: Evofem Reports Financial Results for Third Quarter of 2025, Provides Business Update | -- Increased Net Sales 10% While Lowering Operating Expenses 42% vs. Prior Year Quarter --
-- Delivered $1.0 Million of Operating Income in Q3 2025 --
SAN DIEGO... ► Artikel lesen | |
| CENTENE | 38,045 | -0,25 % | Truist raises Centene stock price target on margin opportunities | ||
| QUIDELORTHO | 19,100 | -1,55 % | QuidelOrtho Corporation: QuidelOrtho Enters Strategic Supply Agreement to Expand Global Immunoassay Portfolio | Agreement adds new analyzer platforms and expands assay menu across key international marketsSAN DIEGO, Feb. 16, 2026 /PRNewswire/ -- QuidelOrtho has entered a long-term strategic supply... ► Artikel lesen | |
| VERU | 2,620 | +2,34 % | Veru Inc.: Veru Reports Fiscal 2026 First Quarter Financial Results and Clinical Program Progress | -- Phase 2b PLATEAU clinical trial evaluating enobosarm in combination with semaglutide in older patients with obesity on track to initiate this quarter- --Company to host conference call and webcast... ► Artikel lesen | |
| NANO-X IMAGING | 2,465 | 0,00 % | Nano-X Imaging Ltd: Nanox Expands in Latin America with Exclusive Nanox.ARC Distribution Agreement in Argentina | Collaboration with Intec SRL drives commercial expansion of 3D medical imaging across a high-growth private healthcare market PETACH TIKVA, Israel, Feb. 19, 2026 (GLOBE NEWSWIRE) -- Nanox Imaging... ► Artikel lesen | |
| TEMPEST THERAPEUTICS | 6,010 | -100,00 % | Tempest Therapeutics: Tempest Announces Interim Results from Ongoing REDEEM-1 Trial of TPST-2003, Preparing for Potential U.S. Registrational Study in 2026 | 100% complete response (CR) rate among all six efficacy evaluable patientsFavorable safety profile with no Grade - 3 CRS or ICANSPrior investigator-initiated trial (IIT) reached median progression... ► Artikel lesen | |
| FULGENT GENETICS | 12,200 | 0,00 % | Fulgent Genetics forecasts $350M 2026 revenue and 53% AP growth as Bako, StrataDx acquisitions reshape customer mix | ||
| LANTHEUS | 64,58 | -1,07 % | Lantheus Holdings, Inc.: Lantheus Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Update | Worldwide revenue of $406.8 million and $1.54 billion for the fourth quarter and full year 2025GAAP fully diluted earnings per share of $0.82 and $3.41 for the fourth quarter and full year 2025Adjusted... ► Artikel lesen | |
| PERSPECTIVE THERAPEUTICS | 4,620 | +0,87 % | Perspective Therapeutics, Inc.: Perspective Therapeutics to Provide Business Highlights and Report Full Year 2025 Financial Results | SEATTLE, Feb. 17, 2026 (GLOBE NEWSWIRE) -- Perspective Therapeutics, Inc. ("Perspective" or the "Company") (NYSE AMERICAN: CATX), a radiopharmaceutical development company pioneering advanced treatments... ► Artikel lesen | |
| AMN HEALTHCARE SERVICES | 17,400 | 0,00 % | AMN Healthcare Services Inc: AMN Healthcare Survey Reveals Sharp Divide Between Leaders' Organizational Confidence and Industry Outlook for 2026 |
Das Unternehmen ACLARION INC kann der Branche Gesundheitswesen zugeordnet werden. Der aktuelle Kurs liegt bei 2,140 Euro und damit +3,38 % im Plus.
VerkaufenHaltenKaufen
■ Verkaufen
■ Halten
■ Kaufen
Sie erhalten auf FinanzNachrichten.de kostenlose Realtime-Aktienkurse von und sowie Kurse und Daten von ARIVA.DE AG.
Weitere Kennzahlen, Fundamentaldaten und Unternehmensinformationen zu ACLARION INC finden Sie auf Wallstreet Online.